Alterations in the topoisomerase II alpha (TOP2A) gene were associated with better patient outcomes following anthracycline-based therapy compared with non-anthracycline-based regimens, according to a study in the April 28 online issue of the Journal of the National Cancer Institute. The increased responsiveness is similar to what is seen in patients whose tumors carry an amplification of the HER2 gene.
More...